Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Monday. The firm issued a hold rating on the medical research company’s stock.

CTSO has been the subject of several other research reports. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research report on Friday, January 3rd. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Cytosorbents presently has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Up 3.8 %

Shares of NASDAQ CTSO opened at $1.08 on Monday. The company has a 50 day simple moving average of $0.92 and a 200-day simple moving average of $1.03. The company has a market capitalization of $59.05 million, a P/E ratio of -3.00 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $1.59.

Institutional Investors Weigh In On Cytosorbents

Several institutional investors have recently modified their holdings of CTSO. Geode Capital Management LLC lifted its position in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares during the last quarter. Sargent Investment Group LLC lifted its position in Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after acquiring an additional 192,747 shares during the last quarter. Finally, Atomi Financial Group Inc. purchased a new stake in Cytosorbents in the third quarter valued at $51,000. 32.87% of the stock is owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.